The Waters Corporation (WAT) Given New $200.00 Price Target at Deutsche Bank AG

The Waters Corporation (WAT) Given New $200.00 Price Target at Deutsche Bank AG

Waters Corporation (NYSE:WAT) had its price target upped by Deutsche Bank AG from $199.00 to $200.00 in a research report report published on Wednesday. Deutsche Bank AG currently has a hold rating on the medical instruments supplier’s stock.

WAT has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Waters Corporation from a hold rating to a buy rating and set a $202.00 target price on the stock in a research note on Thursday, July 13th. Goldman Sachs Group, Inc. (The) began coverage on shares of Waters Corporation in a research note on Tuesday, September 26th. They issued a hold rating and a $180.00 target price on the stock. BidaskClub upgraded shares of Waters Corporation from a buy rating to a strong-buy rating in a research note on Wednesday, August 16th. Jefferies Group LLC restated a hold rating and issued a $175.00 target price on shares of Waters Corporation in a research note on Thursday, July 27th. Finally, Morgan Stanley restated an underweight rating and issued a $183.00 target price (up from $174.00) on shares of Waters Corporation in a research note on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Waters Corporation presently has an average rating of Hold and a consensus price target of $190.71.

Waters Corporation (NYSE:WAT) traded up 1.62% during mid-day trading on Wednesday, hitting $193.44. The company had a trading volume of 401,875 shares. The stock has a 50 day moving average price of $184.68 and a 200-day moving average price of $179.29. The stock has a market capitalization of $15.44 billion, a PE ratio of 29.15 and a beta of 0.81. Waters Corporation has a 1-year low of $133.35 and a 1-year high of $193.76.

Waters Corporation (NYSE:WAT) last issued its quarterly earnings results on Tuesday, October 24th. The medical instruments supplier reported $1.77 EPS for the quarter, beating the consensus estimate of $1.74 by $0.03. The company had revenue of $565.58 million for the quarter, compared to the consensus estimate of $555.25 million. Waters Corporation had a net margin of 24.26% and a return on equity of 23.91%. The firm’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.57 EPS. On average, analysts forecast that Waters Corporation will post $7.40 earnings per share for the current year.

In other news, SVP Rohit Khanna sold 18,400 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $185.78, for a total transaction of $3,418,352.00. Following the transaction, the senior vice president now directly owns 22,477 shares in the company, valued at $4,175,777.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Christopher A. Kuebler sold 3,500 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $179.67, for a total transaction of $628,845.00. Following the transaction, the director now owns 17,849 shares in the company, valued at $3,206,929.83. The disclosure for this sale can be found here. 5.07% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Waters Corporation by 2.8% during the second quarter. Vanguard Group Inc. now owns 7,704,022 shares of the medical instruments supplier’s stock valued at $1,416,308,000 after purchasing an additional 206,262 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Waters Corporation by 3.1% during the second quarter. BlackRock Inc. now owns 5,515,322 shares of the medical instruments supplier’s stock valued at $1,013,936,000 after purchasing an additional 165,611 shares in the last quarter. Fundsmith LLP boosted its stake in shares of Waters Corporation by 11.7% during the second quarter. Fundsmith LLP now owns 3,833,955 shares of the medical instruments supplier’s stock valued at $704,834,000 after purchasing an additional 401,420 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Waters Corporation by 20,670.6% during the second quarter. Janus Henderson Group PLC now owns 1,929,793 shares of the medical instruments supplier’s stock valued at $354,773,000 after purchasing an additional 1,920,502 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Waters Corporation by 7.4% during the second quarter. FMR LLC now owns 1,165,827 shares of the medical instruments supplier’s stock valued at $214,326,000 after purchasing an additional 79,824 shares in the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.

About Waters Corporation

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Related posts

Leave a Comment